This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
04/29/16 - 2:10:49 PM ET (BATS BZX Real-time Price)
Div Yield: --
OMED Day's Range
OMED 52 Week Range
OMED Business Summary
OncoMed Pharmaceuticals, Inc., a clinical development-stage biopharmaceutical company, discovers and develops novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics.View OMED
OncoMed Pharmaceuticals Inc - OMED - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates OncoMed Pharmaceuticals Inc as a
Sell with a ratings score of D.
Report Snippet: We rate ONCOMED PHARMACEUTICALS (OMED) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.